Form 4: Progyny Executive Chairman Schlanger Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
David J. Schlanger, Executive Chairman of Progyny, Inc., sold 71,272 shares of common stock on March 27, 2024, as part of a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 27, 2024, David J. Schlanger, the Executive Chairman of Progyny, Inc., executed a sale of 71,272 shares of Progyny's common stock.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan established on June 23, 2023.
- The shares were sold at a weighted average price of $37.8026, with individual transactions ranging from $37.50 to $38.17.
- Schlanger also exercised stock options to acquire 71,272 shares at an exercise price of $3.9545.
- Following these transactions, Schlanger directly owns 86,312 shares of Progyny's common stock and 1,310,022 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports a routine stock sale under a pre-existing plan. There's no indication of positive or negative implications for the company's future performance.
Industry Context
Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-planned. The market will likely assess the size and frequency of these sales in relation to Schlanger's overall holdings and the company's performance.
Comparison to Industry Standards
- Executive compensation and stock ownership are typical metrics compared against industry peers.
- Companies like Teladoc Health (TDOC) and Accolade (ACCD) are in similar healthcare technology spaces, and their executive compensation structures and insider trading activities could be used as benchmarks.
- However, direct comparisons should consider company size, growth stage, and specific business models.
Stakeholder Impact
- The stock sale could have a minor impact on shareholder sentiment, depending on how the market interprets the transaction.
- However, given that it was pre-planned, the impact is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 06/23/2023 | Date of establishment of the Rule 10b5-1 trading plan. |
| 03/27/2024 | Date of the stock sale and option exercise. |
| 03/29/2024 | Date of the Form 4 filing. |
| 05/23/2029 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.